Press Release

Providence Health Care Becomes First Canadian Center to Adopt Revolutionary HeartFlow FFRCT Analysis to Assess Coronary Artery Disease

REDWOOD CITY, Calif. – July 21, 2016 – Providence Health Care has become the first center in Canada to adopt the HeartFlow® FFRCT Analysis, and also first in the world to utilize the next generation version of the platform. The HeartFlow FFRCT Analysis, which was recently approved by Health Canada, is a novel, non-invasive technology used by clinicians to assess their patients for coronary artery disease.

Developed by HeartFlow, Inc., the HeartFlow FFRCT Analysis is the only non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, aiding clinicians in selecting an appropriate treatment. The latest generation of the HeartFlow FFRCT Analysis is a cloud-based platform that allows for the more rapid processing of cases. The innovative technology has been proven to reduce the need for invasive and costly procedures previously performed to diagnose patients suspected of having coronary artery disease.

“The HeartFlow FFRCT Analysis has the potential to substantially shift the way we diagnose patients with chest pain,” said Jonathon Leipsic, M.D., FRCPC, chairman of the Department of Radiology for Providence Health Care. “The technology offers us a deeper understanding of the extent of the coronary artery disease and risk it poses to the patient. This has very much changed our practice, allowing for more appropriate and personalized treatment decision making.”

Coronary artery disease is the most common type of heart disease. An estimated 1.6 million Canadians are living with the condition, which is the leading cause of death and hospitalization.1 Heart disease costs the Canadian economy more than $20.9 billion every year.2

“Coronary artery disease is not only prevalent but can also be challenging to accurately diagnose with traditional non-invasive tests,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “With our expansion to Canada, we can now help more clinicians diagnose cardiovascular disease non-invasively while reducing unnecessary invasive catheterizations and saving costs.”

The HeartFlow FFRCT Analysis is a web-based platform that aids clinicians in diagnosing coronary artery disease, and provides personalized, actionable information to physicians to manage each patient. The technology solves millions of complex equations simulating blood flow in the coronary arteries to provide mathematically computed fractional flow reserve (FFRCT) values. The result is a personalized color-coded model of the patient’s coronary arteries that aids physicians in determining, vessel-by-vessel, if sufficient blood is reaching the heart.

About HeartFlow, Inc.

HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRCT Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. The novel solution, which produces a model of the patient’s coronary arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow Analysis is commercially available in the United States, Canada, Europe and Japan. For more information visit www.heartflow.com.


  1. Statistics Canada. Causes of Death, Canada, 2011.CANSIM data. Released January 28, 2014
  2. Life time risk and years lived free of total CVD. JAMA, November 7, 2012-Vol 308, No. 17.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.